RESUMEN
Pyruvate kinase (PK) deficiency, a rare, congenital haemolytic anaemia caused by mutations in the PKLR gene, is associated with many clinical manifestations, but the full disease burden has yet to be characterised. The Peak Registry (NCT03481738) is an observational, longitudinal registry of adult and paediatric patients with PK deficiency. Here, we described comorbidities and complications in these patients by age at most recent visit and PKLR genotype. As of 13 May 2022, 241 patients were included in the analysis. In total, 48.3% had undergone splenectomy and 50.5% had received chelation therapy. History of iron overload (before enrolment/during follow-up) was common (52.5%), even in never-transfused patients (20.7%). Neonatal complications and symptoms included jaundice, splenomegaly and hepatomegaly, with treatment interventions required in 41.5%. Among adults, osteopenia/osteoporosis occurred in 19.0% and pulmonary hypertension in 6.7%, with median onset ages of 37, 33 and 22 years, respectively. Biliary events and bone health problems were common across PKLR genotypes. Among 11 patients who had thromboembolic events, eight had undergone prior splenectomy. Patients with PK deficiency may have many complications, which can occur early in and throughout life. Awareness of their high disease burden may help clinicians better provide appropriate monitoring and management of these patients.
Asunto(s)
Anemia Hemolítica Congénita no Esferocítica , Piruvato Quinasa , Errores Innatos del Metabolismo del Piruvato , Sistema de Registros , Humanos , Piruvato Quinasa/deficiencia , Piruvato Quinasa/genética , Masculino , Femenino , Adulto , Niño , Anemia Hemolítica Congénita no Esferocítica/genética , Anemia Hemolítica Congénita no Esferocítica/epidemiología , Errores Innatos del Metabolismo del Piruvato/genética , Errores Innatos del Metabolismo del Piruvato/epidemiología , Adolescente , Preescolar , Lactante , Comorbilidad , Persona de Mediana Edad , Esplenectomía , Adulto Joven , Hipertensión Pulmonar/etiología , Hipertensión Pulmonar/genética , Hipertensión Pulmonar/epidemiología , Sobrecarga de Hierro/etiología , Sobrecarga de Hierro/epidemiología , Enfermedades Óseas Metabólicas/etiología , Enfermedades Óseas Metabólicas/epidemiología , Recién NacidoRESUMEN
INTRODUCTION: Membranopathies encompass haemolytic disorders arising from genetic variants in erythrocyte membrane proteins, including hereditary spherocytosis and stomatocytosis. Congenital dyserythropoietic anaemia type II (CDA II) is associated with the SEC23B gene and can exhibit phenotypic similarities to membranopathies. Current treatment options for these conditions, apart from splenectomy, are primarily supportive. Mitapivat, a novel pyruvate kinase (PK) activator, has demonstrated efficacy in increasing haemoglobin levels and reducing haemolysis in patients with PK deficiency, thalassemia, sickle cell disease and a mouse model of hereditary spherocytosis. METHODS AND ANALYSES: Safety and efficacy of mitapivat sulfate in adult patients with erythrocyte membranopathies (SATISFY) is a prospective, multicentre, single-arm phase two trial involving approximately 25 adult patients (≥18 years) diagnosed with a membranopathy or CDA II. During the 8-week dose escalation period, subjects will receive an initial dose of 50 mg mitapivat two times per day and may increase to 100 mg two times per day at week 4 based on the safety and changes in haemoglobin levels. Patients tolerating mitapivat well may be eligible to continue in two consecutive 24-week fixed dose periods.The primary objective of this study is to evaluate the safety of mitapivat, assessed through the occurrence of treatment-emergent adverse events. Secondary objectives include assessing the effects of mitapivat on haemoglobin levels, haemolysis, erythropoiesis, patient-reported outcome measures and spleen size.SATISFY aims to assess the safety and efficacy of mitapivat in adult patients with red blood cell membranopathies and CDA II, with the aim of establishing proof-of-concept in patients living with these rare conditions. ETHICS AND DISSEMINATION: NCT05935202/CTIS:2023-503271-24-01. Findings will be published in peer-reviewed journals. TRIAL REGISTRATION NUMBER: Clinicaltrials.gov, NCT05935202. CTIS:2023-503271-24-01. Registered 07-July-2023. Protocol number: 2.1. https://clinicaltrials.gov/study/NCT05935202.
Asunto(s)
Piruvato Quinasa , Humanos , Adulto , Proyectos Piloto , Estudios Prospectivos , Piruvato Quinasa/deficiencia , Anemia Diseritropoyética Congénita/tratamiento farmacológico , Ensayos Clínicos Fase II como Asunto , Errores Innatos del Metabolismo del Piruvato/tratamiento farmacológico , Masculino , Femenino , Estudios Multicéntricos como Asunto , Anemia Hemolítica Congénita no EsferocíticaRESUMEN
Clinically meaningful benefits in the signs, symptoms, and impacts of #PKDeficiency as assessed by disease-specific patient-reported outcome measures were observed in mitapivat-treated adult patients in two phase 3 clinical trials.
Asunto(s)
Medición de Resultados Informados por el Paciente , Piruvato Quinasa , Errores Innatos del Metabolismo del Piruvato , Humanos , Piruvato Quinasa/deficiencia , Adulto , Masculino , Femenino , Persona de Mediana Edad , Anemia Hemolítica Congénita no Esferocítica , Resultado del TratamientoRESUMEN
Pyruvate kinase (PK) is a key enzyme of anaerobic glycolysis. The genetic heterogeneity of PK deficiency (PKD) is high, and over 400 unique variants have been identified. Twenty-nine patients who had been diagnosed as PKD genetically in seven distinct paediatric haematology departments were evaluated. Fifteen of 23 patients (65.2%) had low PK levels. The PK:hexokinase ratio had 100% sensitivity for PKD diagnosis, superior to PK enzyme assay. Two novel intronic variants (c.695-1G>A and c.694+43C>T) have been described. PKD should be suspected in patients with chronic non-spherocytic haemolytic anaemia, even if enzyme levels are falsely normal. Total PKLR gene sequencing is necessary for the characterization of patients with PKD and for genetic counselling.
Asunto(s)
Anemia Hemolítica Congénita no Esferocítica , Intrones , Piruvato Quinasa , Errores Innatos del Metabolismo del Piruvato , Humanos , Piruvato Quinasa/deficiencia , Piruvato Quinasa/genética , Masculino , Femenino , Errores Innatos del Metabolismo del Piruvato/genética , Niño , Preescolar , Anemia Hemolítica Congénita no Esferocítica/genética , Turquía , Lactante , Adolescente , MutaciónRESUMEN
Pyruvate kinase (PK) deficiency is a rare autosomal recessive disorder characterized by chronic hemolytic anemia of variable severity. Nine Polish patients with severe hemolytic anemia but normal PK activity were found to carry mutations in the PKLR gene encoding PK, five already known ones and one novel (c.178C > T). We characterized two of the known variants by molecular modeling (c.1058delAAG) and minigene splicing analysis (c.101-1G > A). The former gives a partially destabilized PK tetramer, likely of suboptimal activity, and the c.101-1G > A variant gives alternatively spliced mRNA carrying a premature stop codon, encoding a severely truncated PK and likely undergoing nonsense-mediated decay.
Asunto(s)
Anemia Hemolítica Congénita no Esferocítica , Mutación , Piruvato Quinasa , Errores Innatos del Metabolismo del Piruvato , Humanos , Piruvato Quinasa/genética , Piruvato Quinasa/deficiencia , Polonia , Errores Innatos del Metabolismo del Piruvato/genética , Masculino , Femenino , Anemia Hemolítica Congénita no Esferocítica/genética , Niño , Preescolar , Modelos Moleculares , Lactante , Adolescente , Codón sin Sentido , Empalme AlternativoRESUMEN
Pyruvate kinase (PK) deficiency is the most common cause of chronic congenital non-spherocytic haemolytic anaemia worldwide, with an estimated prevalence of one in 100 000 to one in 300 000 people. PK deficiency results in chronic haemolytic anaemia, with wide ranging and serious consequences affecting health, quality of life, and mortality. The goal of the International Guidelines for the Diagnosis and Management of Pyruvate Kinase Deficiency was to develop evidence-based guidelines for the clinical care of patients with PK deficiency. These clinical guidelines were developed by use of GRADE methodology and the AGREE II framework. Experts were invited after consideration of area of expertise, scholarly contributions in PK deficiency, and country of practice for global representation. The expert panel included 29 expert physicians (including adult and paediatric haematologists and other subspecialists), geneticists, laboratory specialists, nurses, a guidelines methodologist, patients with PK deficiency, and caregivers from ten countries. Five key topic areas were identified, the panel prioritised key questions, and a systematic literature search was done to generate evidence summaries that were used in the development of draft recommendations. The expert panel then met in person to finalise and vote on recommendations according to a structured consensus procedure. Agreement of greater than or equal to 67% among the expert panel was required for inclusion of a recommendation in the final guideline. The expert panel agreed on 31 total recommendations across five key topics: diagnosis and genetics, monitoring and management of chronic complications, standard management of anaemia, targeted and advanced therapies, and special populations. These new guidelines should facilitate best practices and evidence-based PK deficiency care into clinical practice.
Asunto(s)
Anemia Hemolítica Congénita no Esferocítica , Piruvato Quinasa , Errores Innatos del Metabolismo del Piruvato , Humanos , Anemia Hemolítica Congénita no Esferocítica/diagnóstico , Anemia Hemolítica Congénita no Esferocítica/terapia , Piruvato Quinasa/deficiencia , Errores Innatos del Metabolismo del Piruvato/diagnóstico , Errores Innatos del Metabolismo del Piruvato/terapia , Calidad de VidaRESUMEN
ABSTRACT: Pyruvate kinase (PK) deficiency is a rare, hereditary disease characterized by chronic hemolytic anemia. Iron overload is a common complication regardless of age, genotype, or transfusion history. Mitapivat, an oral, allosteric PK activator, improves anemia and hemolysis in adult patients with PK deficiency. Mitapivat's impact on iron overload and ineffective erythropoiesis was evaluated in adults with PK deficiency who were not regularly transfused in the phase 3 ACTIVATE trial and long-term extension (LTE) (#NCT03548220/#NCT03853798). Patients in the LTE received mitapivat throughout ACTIVATE/LTE (baseline to week 96; mitapivat-to-mitapivat [M/M] arm) or switched from placebo (baseline to week 24) to mitapivat (week 24 to week 96; placebo-to-mitapivat [P/M] arm). Changes from baseline in markers of iron overload and erythropoiesis were assessed to week 96. Improvements in hepcidin (mean, 4770.0 ng/L; 95% confidence interval [CI], -1532.3 to 11 072.3), erythroferrone (mean, -9834.9 ng/L; 95% CI, -14 328.4 to -5341.3), soluble transferrin receptor (mean, -56.0 nmol/L; 95% CI, -84.8 to -27.2), and erythropoietin (mean, -32.85 IU/L; 95% CI, -54.65 to -11.06) were observed in the M/M arm (n = 40) from baseline to week 24, sustained to week 96. No improvements were observed in the P/M arm (n = 40) to week 24; however, upon transitioning to mitapivat, improvements similar to those observed in the M/M arm were seen. Mean changes from baseline in liver iron concentration by magnetic resonance imaging at week 96 in the M/M arm and the P/M arm were -2.0 mg Fe/g dry weight (dw; 95% CI, -4.8 to -0.8) and -1.8 mg Fe/g dw (95% CI, -4.4 to 0.80), respectively. Mitapivat is the first disease-modifying pharmacotherapy shown to have beneficial effects on iron overload and ineffective erythropoiesis in patients with PK deficiency. This trial was registered at www.ClinicalTrials.gov as #NCT03548220 (ACTIVATE) and #NCT03853798 (LTE).
Asunto(s)
Anemia Hemolítica Congénita no Esferocítica , Eritropoyesis , Sobrecarga de Hierro , Piruvato Quinasa , Errores Innatos del Metabolismo del Piruvato , Humanos , Sobrecarga de Hierro/etiología , Sobrecarga de Hierro/tratamiento farmacológico , Eritropoyesis/efectos de los fármacos , Adulto , Piruvato Quinasa/deficiencia , Masculino , Femenino , Persona de Mediana Edad , Adulto Joven , Alanina/uso terapéutico , Alanina/análogos & derivados , Piperazinas , QuinolinasRESUMEN
ABSTRACT: Pyruvate kinase (PK) is a key enzyme in glycolysis, the sole source of adenosine triphosphate, which is essential for all energy-dependent activities of red blood cells. Activating PK shows great potential for treating a broad range of hemolytic anemias beyond PK deficiency, because they also enhance activity of wild-type PK. Motivated by observations of sickle-cell complications in sickle-trait individuals with concomitant PK deficiency, activating endogenous PK offers a novel and promising approach for treating patients with sickle-cell disease.
Asunto(s)
Anemia Hemolítica Congénita no Esferocítica , Anemia de Células Falciformes , Piruvato Quinasa/deficiencia , Errores Innatos del Metabolismo del Piruvato , Humanos , Anemia Hemolítica Congénita no Esferocítica/tratamiento farmacológico , Anemia Hemolítica Congénita no Esferocítica/etiología , Eritrocitos , Anemia de Células Falciformes/tratamiento farmacológico , Anemia de Células Falciformes/complicacionesRESUMEN
NICE is unable to make a recommendation on mitapivat (Pyrukynd) for treating pyruvate kinase deficiency in adults because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Asunto(s)
Humanos , Adulto , Piruvato Quinasa/deficiencia , Evaluación de MedicamentosRESUMEN
El déficit de piruvato quinasa es la segunda enzimopatía más frecuente y la principal causa de anemia hemolítica congénita crónica no esferocítica. Su prevalencia está infraestimada por la baja sospecha clínica de los casos leves, las dificultades del correcto diagnóstico enzimático y la gran variedad de diagnósticos diferenciales. Los avances en las técnicas moleculares están permitiendo mejorar notablemente el diagnóstico. El tratamiento continúa basado en soporte transfusional y esplenectomía, siendo necesarios la vigilancia y el tratamiento de la sobrecarga férrica en todos los pacientes, transfundidos o no. Actualmente el único tratamiento curativo es el trasplante alogénico de progenitores hematopoyéticos, indicado en los casos graves con donante idéntico. Las nuevas terapias farmacológicas y génicas parecen prometedoras. En este artículo, el Grupo Español de Eritropatología realiza una actualización de la situación actual de esta enfermedad, con especial atención a los métodos diagnósticos y a los tratamientos actuales y futuros. (AU)
Pyruvate kinase (PK) deficiency is the second most frequent enzymopathy and the most common cause of chronic hereditary non-spherocytic haemolytic anaemia. Its global prevalence is underestimated due to low clinical suspicion of mild cases, associated with difficulties in the performance and interpretation of PK enzymatic activity assays. With the advent of next generation sequencing techniques, a better diagnostic approach is achieved. Treatment remains based on red blood cell transfusions and splenectomy, with special attention to iron overload, not only in transfusion-dependent patients. Nowadays, allogeneic hematopoietic stem cell transplantation is the only curative treatment, recommended only in selected cases of severely affected patients with an HLA-identical donor. Novel pharmacological and gene therapies are in clinical trials, with promising results. In this article, the Spanish Erythropathology Group reviews the current situation of PK deficiency, paying special attention to the usefulness of different diagnostic techniques and to actual and emerging treatments. (AU)
Asunto(s)
Humanos , Anemia Hemolítica Congénita no Esferocítica/diagnóstico , Anemia Hemolítica Congénita no Esferocítica/genética , Consenso , Piruvato Quinasa/deficiencia , Piruvato Quinasa/genéticaRESUMEN
No disponible
Asunto(s)
Humanos , Femenino , Adulto , Cintigrafía/métodos , Esplenosis/diagnóstico por imagen , Eritrocitos/efectos de la radiación , Esplenectomía , Anemia Hemolítica/complicaciones , Piruvato Quinasa/deficiencia , Sensibilidad y EspecificidadRESUMEN
Abstract Background: Pyruvate kinase deficiency is a hereditary disease that affects the glycolytic pathway of the red blood cell, causing nonspherocytic hemolytic anemia. The disease is transmitted as an autosomal recessive trait and shows a marked variability in clinical expression. This study reports on the molecular characterization of ten Brazilian pyruvate kinase-deficient patients and the genotype-phenotype correlations. Method: Sanger sequencing and in silico analysis were carried out to identify and characterize the genetic mutations. A non-affected group of Brazilian individuals were also screened for the most commonly reported variants (c.1456C>T and c.1529G>A). Results: Ten different variants were identified in the PKLR gene, of which three are reported here for the first time: p.Leu61Gln, p.Ala137Val and p.Ala428Thr. All the three missense variants involve conserved amino acids, providing a rationale for the observed enzyme deficiency. The allelic frequency of c.1456C>T was 0.1% and the 1529G>A variant was not found. Conclusion: This is the first comprehensive report on molecular characterization of pyruvate kinase deficiency from South America. The results allowed us to correlate the severity of the clinical phenotype with the identified variants.
Asunto(s)
Humanos , Masculino , Femenino , Piruvato Quinasa/deficiencia , Eritrocitos , Anemia Hemolítica , MutaciónRESUMEN
Antecedentes y objetivo: El déficit de piruvato cinasa (DPK) es una enfermedad hereditaria rara, que cursa con hemólisis crónica y anemia de intensidad variable. Su heterogeneidad genética es elevada, habiéndose descrito unas 240 mutaciones diferentes. Pacientes y metodología: Se han estudiado 15 pacientes con DPK en los que se ha secuenciado la totalidad del gen PKLR, incluyendo las regiones promotora, exónicas, intrónicas flanqueantes y 3UTR. Resultados: Según la intensidad del cuadro clínico, los pacientes se han clasificado en 3 grandes grupos: I) grave y muy grave (8 pacientes); II) moderado (2 pacientes), y III) leve (5 pacientes). Se han identificado 18 alelos diferentes, de los que 6 son mutaciones nuevas, no descritas con anterioridad, siendo la mutación PKLRc.721G > T la más prevalente (26,67%), seguida de la mutación PKLR c.1456C > T (13,33%). Trece de los 15 pacientes mostraron un genotipo doble heterocigoto y 2 homocigoto. Conclusiones: En España, la heterogeneidad del patrón genético de la PKLR continúa siendo elevada, aunque algo diferente a la observada en un estudio anterior (1998). Se concluye que la secuenciación total del gen PKLR es imprescindible tanto para la caracterización de los pacientes como para la realización del consejo genético (AU)
Background and objective: Pyruvate kinase deficiency (PKD) is a rare, inherited disease causing chronic hemolysis and anemia of varying intensity. The genetic heterogeneity of PKD is high and, to this day, over 240 different mutations have been identified. Patients and methods: 15 unrelated patients affected by PKD have been studied. PKLR gene sequencing was performed by SANGER, including the determination of promoter regions, exonic, intronic flanking and 3UTR. Results: Patients were classified into 3 groups based on the intensity of their clinical symptoms: I) severe and very severe (8 patients); II) moderate (2 patients), and III) mild (5 patients). Six out of the 18 alleles found were new mutations which had not been described previously, with the PKLR c.721G>T mutation being the most prevalent (26.67%), followed by the PKLR c.1456C>T mutation (13.33%). Conclusions: In Spain, the genetic heterogeneity of PKLR is still high but differs from that observed in the previous study carried out in 1998. Total PKLR gene sequencing is necessary for the characterization of all patients with PKD and for genetic counseling (AU)
Asunto(s)
Humanos , Piruvato Quinasa/deficiencia , Anemia Hemolítica/genética , Índice de Severidad de la Enfermedad , Análisis de Secuencia de ADN , Variación Genética , AlelosRESUMEN
No disponible
Asunto(s)
Humanos , Niño , Errores Innatos del Metabolismo/diagnóstico , Deficiencia de Glucosafosfato Deshidrogenasa/diagnóstico , Piruvato Quinasa/deficiencia , Hemólisis , Fosfofructoquinasas/deficiencia , Fosfoglicerato Quinasa/deficienciaAsunto(s)
Humanos , Femenino , Persona de Mediana Edad , Neoplasias del Mediastino/diagnóstico , Sistema Hematopoyético , Médula Ósea , Neurofibrosarcoma/complicaciones , Neurofibrosarcoma , Exametazima de Tecnecio Tc 99m , Radiografía Torácica , Neoplasias del Mediastino , Piruvato Quinasa/deficienciaRESUMEN
No disponible
Asunto(s)
Humanos , Piruvato Quinasa/deficiencia , Anemia Hemolítica/enzimología , Eritrocitos/enzimología , Errores Innatos del Metabolismo/enzimologíaRESUMEN
Pyruvate kinase (PK) deficiency is a rare red cell glycolytic enzymopathy. The purpose of the present investigation was to offer prenatal diagnosis for PK deficiency to a couple who had a previous child with severe enzyme deficiency and congenital non-spherocytic hemolytic anemia. PK deficiency was identified in the family by assaying the enzyme activity in red cells. Chorionic villus sampling was performed in an 11-week gestation and the mutation was located in exon 10 of the PKLR gene characterized by polymerase chain reaction and using restriction endonuclease digestion with the MspI enzyme, which was confirmed by DNA sequencing on the ABI 310 DNA sequencer. Both the parents were heterozygous for the 1436G-->A [479 Arg-->His] mutation in exon 10 and the proband was homozygous for this mutation. The fetus was also heterozygous for this mutation and the pregnancy was continued. Prenatal diagnosis allowed the parents with a severely affected child with PK deficiency to have the reproductive choice of having the fetus tested in a subsequent pregnancy.
Asunto(s)
Humanos , Masculino , Femenino , Embarazo , Anemia Hemolítica Congénita no Esferocítica/diagnóstico , Diagnóstico Prenatal/métodos , Mutación , Piruvato Quinasa/deficiencia , Piruvato Quinasa/genética , Anemia Hemolítica Congénita no Esferocítica/genética , Anemia Hemolítica/genética , Análisis Mutacional de ADN , Enzimas de Restricción del ADN/metabolismo , Homocigoto , Primer Trimestre del Embarazo , Exones , IndiaRESUMEN
La deficiencia de piruvato cinasa es una causa rara de anemia hemolítica. Durante el embarazo, se ha tratado casos graves de esta deficiencia con transfusiones profilácticas de concentrados de hematíes para mantener unos valores de hemoglobina entre 7 y 8 g/dl. Caso clínico. Se descubrió un caso de anemia hemolítica secundaria a déficit de piruvato cinasa durante el primer embarazo de una mujer de 32 años. La anemia se trató con transfusiones de concentrados de hematíes, y en la segunda gestación fue necesario un mayor número de ellas para mantener los valores de hemoglobina por encima de 7 g/dl. En ambos casos, los recién nacidos tuvieron pesos en el percentil adecuado para su edad gestacional. Conclusiones. Este tipo de anemia es raro, y en ocasiones se descubre en situaciones especiales, como embarazo, infección o estrés (AU)
Pyruvate kinase deficiency is a rare cause of hemolytic anemia. During pregnancy, severe cases have traditionally been treated with prophylactic blood transfusions to maintain the hemoglobin concentration above arbitrary thresholds of 7-8 g/dL. Case report. A case of hemolytic anemia due to pyruvate kinase deficiency was discovered during the first pregnancy of a 32-year-old woman. The anemia was treated with blood transfusions. In a second pregnancy, the patient required a greater number of transfusions to keep the hemoglobin concentration above 7 g/dL. Both newborns were healthy and had adequate birth weight for gestational age. Conclusions. This kind of anemia is rare and sometimes occurs in special situations such as pregnancy, infection, or stress (AU)